Insulins

Last updated: January 18, 2022

Insulins

Watch later

Watch later

TF/Px ratio and TF/Pinulin
Measuring renal plasma flow and renal blood flow
Regulation of renal blood flow
Tubular reabsorption and secretion
Hypocalcemia
Renal tubular acidosis
Minimal change disease
Diabetic nephropathy
Focal segmental glomerulosclerosis (NORD)
Amyloidosis
Membranous nephropathy
Lupus nephritis
Poststreptococcal glomerulonephritis
Rapidly progressive glomerulonephritis
IgA nephropathy (NORD)
Alport syndrome
Kidney stones
Hydronephrosis
Acute pyelonephritis
Chronic pyelonephritis
Prerenal azotemia
Renal azotemia
Acute tubular necrosis
Postrenal azotemia
Renal papillary necrosis
Renal cortical necrosis
Chronic kidney disease
Polycystic kidney disease
Multicystic dysplastic kidney
Medullary cystic kidney disease
Medullary sponge kidney
Renal artery stenosis
Renal cell carcinoma
Angiomyolipoma
Nephroblastoma (Wilms tumor)
WAGR syndrome
Beckwith-Wiedemann syndrome
Posterior urethral valves
Hypospadias and epispadias
Vesicoureteral reflux
Bladder exstrophy
Urinary incontinence
Neurogenic bladder
Lower urinary tract infection
Transitional cell carcinoma
Non-urothelial bladder cancers
Congenital renal disorders: Pathology review
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Urinary tract infections: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Thiazide and thiazide-like diuretics
Potassium sparing diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Endocrine system anatomy and physiology
Hunger and satiety
Insulin
Glucagon
Somatostatin
Diabetes mellitus
Diabetic retinopathy
Pancreatic neuroendocrine neoplasms
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes insipidus and SIADH: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Diabetes mellitus: Pathology review
Prostate cancer
Prostate gland histology
Hyperthyroidism
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Euthyroid sick syndrome
Thyroid hormones
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Hypothyroidism
Thyroglossal duct cyst
Riedel thyroiditis
Thyroid cancer
Congenital adrenal hyperplasia
Primary adrenal insufficiency
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal cortical carcinoma
Cushing syndrome
Conn syndrome
Hyperparathyroidism
Hypoparathyroidism
Hyperpituitarism
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Gigantism
Acromegaly
Hypopituitarism
Pituitary apoplexy
Sheehan syndrome
Hypoprolactinemia
Constitutional growth delay
Diabetes insipidus
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Precocious puberty
Delayed puberty
Premature ovarian failure
Polycystic ovary syndrome
Androgen insensitivity syndrome
Kallmann syndrome
5-alpha-reductase deficiency
Autoimmune polyglandular syndrome type 1 (NORD)
Multiple endocrine neoplasia
Zollinger-Ellison syndrome
Carcinoid syndrome
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Multiple endocrine neoplasia: Pathology review
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Synthesis of adrenocortical hormones
Cortisol
Testosterone
Estrogen and progesterone
Parathyroid hormone
Calcitonin
Adrenocorticotropic hormone
Growth hormone and somatostatin
Oxytocin and prolactin
Pituitary gland histology
Pancreas histology
Thyroid and parathyroid gland histology
Adrenal gland histology
Iron deficiency anemia
Alpha-thalassemia
Beta-thalassemia
Sideroblastic anemia
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Anemia of chronic disease
Lead poisoning
Hemolytic disease of the newborn
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Hereditary spherocytosis
Sickle cell disease (NORD)
Fanconi anemia
Megaloblastic anemia
Folate (Vitamin B9) deficiency
Aplastic anemia
Vitamin B12 deficiency
Diamond-Blackfan anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Hemophilia
Vitamin K deficiency
Hemolytic-uremic syndrome
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antiphospholipid syndrome
Antithrombin III deficiency
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Leukemoid reaction
Langerhans cell histiocytosis
Multiple myeloma
Monoclonal gammopathy of undetermined significance
Waldenstrom macroglobulinemia
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Anatomy of the thyroid and parathyroid glands
Pharyngeal arches, pouches, and clefts
Blood histology
Blood components
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Anatomy clinical correlates: Other abdominal organs
Anatomy of the male urogenital triangle
Membranoproliferative glomerulonephritis

Transcript

Watch video only

Insulin is a type of peptide hormone that reduces the amount of glucose in the blood. It is produced in the pancreas by beta cells. These cells are found within clusters of endocrine cells called the Islets of Langerhans, which are distributed across the pancreas. If the body is unable to produce enough insulin, then insulin therapy is used to keep the blood glucose low.

Insulin’s main function is to facilitate the transport of glucose from the blood into the various insulin-responsive tissues like muscle cells and adipose tissue. This hormone binds to insulin receptors on the surface of the cell membrane. Now, these receptors have two alpha and two beta subunits. Alpha subunits are located outside of the cell and they bind insulin; while two beta subunits are located within the cell and they have tyrosine kinase activity which carries signals into the cell. Once stimulated, insulin receptors cause intracellular storage vesicles, which contain glucose transport proteins called GLUT4, to fuse with the cell membrane. Next, the GLUT4 proteins embed themselves into the membrane and allow glucose to move into the cell.

As a result, insulin promotes glucose uptake and glycogenesis, which is the conversion of glucose to glycogen. Glycogenesis is the process that takes place in the liver and skeletal muscles. When glycogen storage capacity is reached, insulin promotes glycolysis, which is the breakdown of glucose to pyruvate. It also stimulates lipogenesis, the synthesis of fatty acids and triglycerides in the liver and adipose tissue; and amino acid uptake and protein synthesis in skeletal muscles.

Finally, insulin activates Na+/K+- ATPase pumps and shifts potassium into intracellular space, thereby decreasing potassium levels in the blood. On the flip side, insulin inhibits glycogenolysis, which stands for the breakdown of glycogen; and gluconeogenesis, which is glucose production from lactic acids and noncarbohydrate molecules. Finally, insulin inhibits lipolysis, the breakdown of lipids; and proteolysis, the breakdown of proteins.

Type 1 diabetes mellitus, which most commonly affects children and adolescents, arises when a person’s own T cells attack the pancreas. Normally, maturing T cells in our body go through a process called “self-tolerance” where the T cells that would attack our own body are eliminated. In type 1 diabetes, there is a genetic abnormality which causes the loss of self-tolerance among T cells that target the beta cells. The result is the destruction of the beta cells which leads to decreased insulin production and hyperglycemia, or increased blood glucose.

Type 2 diabetes is caused by insulin resistance in the cells of the body. When blood glucose rises after a meal, the pancreas produces insulin as a response. Since the peripheral cells are resistant to insulin, they do not take in the glucose, so the pancreas has to produce even more insulin. Eventually, the poor pancreas gets so overworked that the beta cell starts to atrophy, which leads to decreased insulin production and high blood glucose levels.

In order to correct the insulin deficiency found in Type 1 diabetes and later stages of type 2 diabetes, exogenous insulins can be used. Insulin is administered subcutaneously because they can be broken down in the GI tract. Insulin is typically administered through syringes or insulin pens. When injected into the abdominal region, the absorption is the quickest, followed by arms, thighs, and buttocks. Some diabetics prefer the insulin pump since insulin dosages are programmed into the device and will be delivered subcutaneously throughout the day, thus preventing the need for multiple daily insulin injections.

Now, there are multiple categories of insulin therapies, more commonly referred to as insulin preparations. These preparations are categorized according to their onset of action and duration of effect; and they include rapid-acting, short-acting, intermediate-acting, long-acting, and ultra long-acting insulins.

Rapid-acting and short-acting insulins are used for bolus insulin regimen, where they are taken before each meal to counteract the post-meal increase in blood glucose. Intermediate-acting, long-acting, and ultra long-lasting insulins are used for basal insulin regimen to maintain a steady background level of insulin throughout the day. They are given once or twice daily to regulate the basal, or fasting blood glucose, level.

Next, there's a basal-bolus regimen where a basal insulin is used to maintain fasting blood glucose levels, and a bolus insulin is taken before meals. Lastly, is the sliding-scale regimen. This regimen is typically reserved for hospital settings where a person’s blood glucose level could fluctuate rapidly due to metabolic stressors like infections or other illnesses. In this regimen, every 4-6 hours, the person’s glucose level is measured and an appropriate dosage of short acting insulin is given. Finally, it’s important to note that insulins are the preferred medications in managing diabetes in pregnancy and breastfeeding.

Now let’s look at each class of insulin, starting with rapid-acting insulins, which include insulin aspart, lispro, and glulisine. These medications are given subcutaneously and they are actually modified versions of regular insulin with different sequences of amino acids. This makes them less stable, and they break down into single monomers soon after injection. Rapid-acting insulins begin working within 5 to 15 minutes of administration, with a peak effect at 1 hour. Their effects last for 3 to 4 hours. These insulins are injected right before a meal or they can be used in insulin pumps. They are also the preferred insulin for treating diabetic ketoacidosis.

Next are the short-acting insulins, or regular insulin, which is the only type of insulin that could be given subcutaneously and intravenously. Regular insulin in the body is generally produced and stored as a hexamer, which is simply a term used to describe a single unit of 6 insulin molecules. This structure allows insulin to remain stable within the body, and break down into individual monomers in order to become active. Thus, regular insulin only begins working 30 minutes after administration and its effect peaks at 2-3 hours. Its duration of action lasts between 5-8 hours and, besides diabetes melitus, it can be used to treat hyperkalemia.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Insulin lispro: a fast-acting insulin analog" Am Fam Physician (1998)
  5. "Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation" Pharmaceutical Research (2017)
  6. "Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus" Cochrane Database of Systematic Reviews (2016)